Qlife Holding AB (QLIFE) - Net Assets
Based on the latest financial reports, Qlife Holding AB (QLIFE) has net assets worth Skr-7.51 Million SEK (≈ $-807.98K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr9.63 Million ≈ $1.04 Million USD) and total liabilities (Skr17.14 Million ≈ $1.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Qlife Holding AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-7.51 Million |
| % of Total Assets | -77.95% |
| Annual Growth Rate | N/A |
| 5-Year Change | -104.6% |
| 10-Year Change | N/A |
| Growth Volatility | 80.34 |
Qlife Holding AB - Net Assets Trend (2019–2025)
This chart illustrates how Qlife Holding AB's net assets have evolved over time, based on quarterly financial data. Also explore Qlife Holding AB total assets for the complete picture of this company's asset base.
Annual Net Assets for Qlife Holding AB (2019–2025)
The table below shows the annual net assets of Qlife Holding AB from 2019 to 2025. For live valuation and market cap data, see QLIFE company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr-7.51 Million ≈ $-807.98K |
-425.40% |
| 2024-12-31 | Skr-1.43 Million ≈ $-153.78K |
+93.82% |
| 2023-12-31 | Skr-23.12 Million ≈ $-2.49 Million |
-125.37% |
| 2022-12-31 | Skr91.15 Million ≈ $9.81 Million |
-44.14% |
| 2021-12-31 | Skr163.18 Million ≈ $17.56 Million |
+82.22% |
| 2020-12-31 | Skr89.55 Million ≈ $9.64 Million |
+43.33% |
| 2019-12-31 | Skr62.48 Million ≈ $6.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Qlife Holding AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27368700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.51 Million | % |
| Other Components | Skr269.30 Million | % |
| Total Equity | Skr-7.51 Million | 100.00% |
Qlife Holding AB Competitors by Market Cap
The table below lists competitors of Qlife Holding AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Real Estate Credit Investments Limited
LSE:RECI
|
$3.24 Million |
|
Chatham Rock Phosphate Ltd
V:NZP
|
$3.25 Million |
|
TFP Solutions Bhd
KLSE:0145
|
$3.25 Million |
|
RevoluGROUP Canada Inc
V:REVO
|
$3.26 Million |
|
Victorian Plumbing Group PLC
LSE:VIC
|
$3.24 Million |
|
Comanche International Public Company Limited
BK:COMAN
|
$3.24 Million |
|
iCoreConnect Inc. Common stock
NASDAQ:ICCT
|
$3.23 Million |
|
COLLPLANT BIOTECH. IS-01
F:CPT
|
$3.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qlife Holding AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,429,000 to -7,508,000, a change of -6,079,000.
- Net loss of 20,558,000 reduced equity.
- Other factors increased equity by 14,479,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-20.56 Million | -273.81% |
| Other Changes | Skr14.48 Million | +192.85% |
| Total Change | Skr- | % |
Book Value vs Market Value Analysis
This analysis compares Qlife Holding AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | Skr5.80 | Skr1.92 | x |
| 2020-12-31 | Skr1.13 | Skr1.92 | x |
| 2021-12-31 | Skr1.56 | Skr1.92 | x |
| 2022-12-31 | Skr0.85 | Skr1.92 | x |
| 2023-12-31 | Skr-0.02 | Skr1.92 | x |
| 2024-12-31 | Skr0.00 | Skr1.92 | x |
| 2025-12-31 | Skr-0.60 | Skr1.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qlife Holding AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6345.06%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-23.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -8.44% | -45.38% | 0.15x | 1.23x | Skr-11.52 Million |
| 2020 | -22.56% | -97.35% | 0.16x | 1.42x | Skr-29.15 Million |
| 2021 | -29.28% | -97.94% | 0.20x | 1.46x | Skr-52.05 Million |
| 2022 | -102.19% | -517.65% | 0.09x | 2.11x | Skr-102.26 Million |
| 2023 | 0.00% | -65555.74% | 0.01x | 0.00x | Skr-157.64 Million |
| 2024 | 0.00% | -111962.00% | 0.00x | 0.00x | Skr-55.84 Million |
| 2025 | 0.00% | -6345.06% | 0.03x | 0.00x | Skr-19.81 Million |
Industry Comparison
This section compares Qlife Holding AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qlife Holding AB (QLIFE) | Skr-7.51 Million | -8.44% | N/A | $3.24 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Qlife Holding AB
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Its biomarkers include CRP/C-reactive protein, procalcitonin, Nt-pro-BNP, lipids, HbA1c/D-vit… Read more